Fahad Alam
Internal Medicine · Lincoln, NENPI 1518457894
Payments from drug & device makers
Across 48 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$161
- Boehringer Ingelheim$143
- Bayer$142
- Actelion Pharmaceuticals US, Inc.$77
- AbbVie$54
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$49
- plus $435 from 20 others
What the payments were for
- Food & beverage$1,062100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $161 |
| Boehringer Ingelheim | 4 | $143 |
| Bayer | 5 | $142 |
| Actelion Pharmaceuticals US, Inc. | 1 | $77 |
| AbbVie | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Astellas Pharma US Inc | 2 | $48 |
| AstraZeneca(2 entities) | 2 | $45 |
| Amgen | 2 | $33 |
| Boston Scientific | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Antares Pharma, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| GSK | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Abbott | 1 | $10 |
How this compares
$1,062 in reported general payments places this provider in the 80th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $72,837 |
| JardianceEmpagliflozin | 41 | $44,981 |
| EliquisApixaban | 54 | $44,735 |
| XareltoRivaroxaban | 48 | $35,607 |
| OzempicSemaglutide | 22 | $33,999 |
| MyrbetriqMirabegron | 47 | $26,286 |
| MounjaroTirzepatide | 12 | $19,761 |
| JanuviaSitagliptin Phosphate | 11 | $15,981 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $11,208 |
| LinzessLinaclotide | 18 | $9,704 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $9,578 |
| Novolog FlexpenInsulin Aspart | 12 | $8,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,663 |
| Gabapentin | 224 | $5,130 |
| MovantikNaloxegol Oxalate | 13 | $5,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $45 | $72,83777 claims |
| PfizerEliquis, Paxlovid | $22 | $46,16470 claims |
| Boehringer IngelheimJardiance | $143 | $44,98141 claims |
| Johnson & JohnsonXarelto | $16 | $35,60748 claims |
| Novo NordiskOzempic | $161 | $33,99922 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $26,28647 claims |
| Lilly USA, LLCMounjaro | $17 | $19,76112 claims |
| AbbVieLinzess, Synthroid | $54 | $11,63749 claims |
| GSKTrelegy Ellipta | $18 | $7,66312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Lincoln
- Scott RasmussenLincoln$38.1M
- Alexander RyanLincoln$2.2M
- Jason PottsLincoln$686K
- Sherri ThomasLincoln$136K
- Aaron WardLincoln$40K
- Anthony RossLincoln$6K
- Wasim ChughtaiLincoln$6K
- Mary DreyLincoln$6K
- Charles HarperNorfolk$31.1M
- Robert SchwabBoys Town$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.